[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69834921D1 - Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält - Google Patents

Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält

Info

Publication number
DE69834921D1
DE69834921D1 DE69834921T DE69834921T DE69834921D1 DE 69834921 D1 DE69834921 D1 DE 69834921D1 DE 69834921 T DE69834921 T DE 69834921T DE 69834921 T DE69834921 T DE 69834921T DE 69834921 D1 DE69834921 D1 DE 69834921D1
Authority
DE
Germany
Prior art keywords
antigen
adjuvanties
derivated
monoglycerides
diglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834921T
Other languages
English (en)
Other versions
DE69834921T2 (de
Inventor
Sveinbjoern Gizurarson
Vera Gudmundsdottir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LYFJATHROUN H F ICELANDIC
Original Assignee
LYFJATHROUN H F ICELANDIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LYFJATHROUN H F ICELANDIC filed Critical LYFJATHROUN H F ICELANDIC
Publication of DE69834921D1 publication Critical patent/DE69834921D1/de
Application granted granted Critical
Publication of DE69834921T2 publication Critical patent/DE69834921T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
DE69834921T 1997-07-09 1998-07-09 Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält Expired - Fee Related DE69834921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS451897 1997-07-09
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
PCT/IS1998/000006 WO1999002186A2 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant

Publications (2)

Publication Number Publication Date
DE69834921D1 true DE69834921D1 (de) 2006-07-27
DE69834921T2 DE69834921T2 (de) 2007-01-18

Family

ID=36699745

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834921T Expired - Fee Related DE69834921T2 (de) 1997-07-09 1998-07-09 Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält

Country Status (13)

Country Link
US (2) US6514503B1 (de)
EP (1) EP1003551B1 (de)
JP (1) JP2001509491A (de)
KR (1) KR20010021622A (de)
CN (1) CN1202863C (de)
AT (1) ATE329617T1 (de)
AU (1) AU745849B2 (de)
BR (1) BR9810568A (de)
CA (1) CA2295237A1 (de)
DE (1) DE69834921T2 (de)
ES (1) ES2267189T3 (de)
IS (2) IS4518A (de)
WO (1) WO1999002186A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
DE69937343T2 (de) * 1998-05-07 2008-07-24 Corixa Corp., Seattle Adjuvanszusammensetzung und methoden zu deren verwendung
WO2000069456A2 (en) 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
DE69937580D1 (de) * 1999-08-18 2007-12-27 Ind Academic Coop Agent zur induktion einer immunologischen toleranz
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB0007465D0 (en) * 2000-03-29 2000-05-17 Amersham Pharm Biotech Uk Ltd Substrate for a lipase enzyme assay
IL153133A0 (en) * 2000-06-22 2003-06-24 American Cyanamid Co Qs-21 and il-12 as an adjuvant combination
PL366031A1 (en) * 2000-11-10 2005-01-24 Wyeth Holdings Corporation Adjuvant combination formulations
CN1541111A (zh) * 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
CN1977971A (zh) * 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
US20040241310A1 (en) * 2001-08-16 2004-12-02 Sveibjorn Gizurarson Method of producing antibodies ex-vivo
WO2003047493A2 (en) * 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
CA2477321A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
AU2003205979A1 (en) * 2002-02-25 2003-09-09 Lyfjathroun Hf, Biopharmaceutical Research An immunological adjuvant
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
WO2004046693A1 (ja) * 2002-11-21 2004-06-03 Sapporo Immuno Diagnostic Laboratory 唾液の採取および回収器具
AU2003299722A1 (en) * 2002-12-17 2004-07-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
US20060264505A1 (en) * 2003-11-07 2006-11-23 Stiefel Laboratories, Inc. Dermatological compositions
CN1909921B (zh) * 2003-11-10 2012-09-26 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
EP1917976B1 (de) 2005-08-01 2011-03-16 Hisamitsu Pharmaceutical Co. Inc. Adjuvans oder pharmazeutische zubereitung zur transdermalen oder transmukosalen verabreichung
JP5081243B2 (ja) * 2006-08-17 2012-11-28 ザ ユーエービー リサーチ ファウンデーション 肺炎球菌抗原を被検体における肺炎球菌性肺炎の指標とする方法
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
EP2164957B1 (de) 2007-05-23 2017-07-12 The UAB Research Foundation Enttoxifizierte neuraminidase aus pneumococcus und ihre verwendungen
WO2010041143A2 (en) * 2008-10-08 2010-04-15 Immune Solutions Limited Oral vaccines for producing mucosal immunity
WO2010105047A2 (en) * 2009-03-11 2010-09-16 Monsanto Technology Llc Herbicidal formulations comprising glyphosate and alkoxylated glycerides
JP5762307B2 (ja) * 2009-03-31 2015-08-12 国立感染症研究所長 経鼻投与用ワクチンを用いるインフルエンザの予防方法
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6114401B2 (ja) 2013-10-31 2017-04-12 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008517A2 (en) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
NL195510A (de) * 1955-03-11
FR2253499B1 (de) * 1973-12-10 1977-11-04 Fabre Sa Pierre
US4420484A (en) * 1979-08-13 1983-12-13 Sterling Drug Inc. Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS60149510A (ja) * 1984-01-13 1985-08-07 Kao Corp 農薬組成物
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4771571A (en) * 1986-12-31 1988-09-20 Nabisco Brands, Inc. Method for treating pineapple to prevent pineapple fruit diseases
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
EP0324455A3 (de) 1988-01-15 1991-03-27 Hans O. Ribi Neue polymerische Immuno-Adjuvans
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
GB9207799D0 (en) 1992-04-09 1992-05-27 Procter & Gamble Aqueous compositions
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU679013B2 (en) * 1992-10-16 1997-06-19 Ibah, Inc. Convertible microemulsion formulations
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
AU6018894A (en) * 1993-01-15 1994-08-15 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DK0722323T3 (da) * 1994-08-05 2000-04-03 Inpharma Sa Præparater indeholdende troxerutin komplekseret med phosphatidylcholin til topisk behandling af erektil impotens
FR2729307B1 (fr) 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
EP0833621B1 (de) * 1995-06-09 2002-01-30 R.P. Scherer Technologies, Inc. Weichgelatinekapsel mit teilchenmaterial
TW410158B (en) 1995-11-30 2000-11-01 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine and method for preparing same
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
FR2773489B1 (fr) * 1998-01-15 2001-03-23 Immunotech Sa Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034792A1 (de) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasale Verabreichung von Pneumokokken-Polysaccharid Impfstoffen
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
WO1999002186A2 (en) 1999-01-21
US20030099659A1 (en) 2003-05-29
JP2001509491A (ja) 2001-07-24
ES2267189T3 (es) 2007-03-01
IS5329A (is) 1999-12-29
AU8459898A (en) 1999-02-08
CN1262626A (zh) 2000-08-09
KR20010021622A (ko) 2001-03-15
US6514503B1 (en) 2003-02-04
AU745849B2 (en) 2002-04-11
BR9810568A (pt) 2000-09-19
WO1999002186A3 (en) 1999-04-01
EP1003551A2 (de) 2000-05-31
DE69834921T2 (de) 2007-01-18
IS4518A (is) 1999-01-10
CA2295237A1 (en) 1999-01-21
ATE329617T1 (de) 2006-07-15
EP1003551B1 (de) 2006-06-14
CN1202863C (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
DE69834921D1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
WO2001034801A3 (en) Recombinant gelatin in vaccines
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE3852761D1 (de) Saponin-hilfsmittel.
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
ATE217795T1 (de) Saponin-antigen-konjugate und ihre verwendung
JPS546787A (en) Luminous element
GB9905911D0 (en) Method
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
MY116128A (en) Vaccine composition
ES2193240T3 (es) Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DE3877594D1 (de) Gaserzeugende zusammensetzung.
DE69940774D1 (de) Hla-bindende peptide und ihre verwendungen
FR2715304B1 (fr) Vaccin anti-allergique.
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NO154969C (no) Fremgangsmaate for fremstilling av brensel, saerlig til bruk i hvirvelbrennere, samt anvendelse av samme.
DE69840438D1 (en) Antigen
DK0589348T4 (da) Fremgangsmåde til immunkemisk kvantificering af inaktiverede antigener
AR012896A1 (es) Polipeptido flge de helicobacter pylori, composicion de vacuna, uso de dicho polipeptido para la fabricacion de composiciones, metodo de diagnostico invitro, y kit de diagnostico para la deteccion de la infeccion por helicobacter pylori
ITBN980003A1 (it) Pareti trasparenti fisse e mobili per stufe, termocamini, termocucine, camini, cucine, forni, riscaldatori e simili; che nel funzionamento ne abbelliscono la visione trasformandosi dopo in un ornamento.
IT7925043A0 (it) Elemento prefabbricato tridimensionale per edilizia, fungente anche da rivestimento per mobili e simili.
WO1999027955A3 (en) Treatment of established chronic infections and cancers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee